| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/30/2006 | EP1696030A1 TIE ligand homologues |
| 08/30/2006 | EP1696029A1 TIE ligand homologues |
| 08/30/2006 | EP1696028A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 08/30/2006 | EP1696027A1 Hla-dr-binding antigen peptide derived from wt1 |
| 08/30/2006 | EP1695986A2 Anti-erb B2 antibodies |
| 08/30/2006 | EP1695985A2 Humanized antibodies and methods for forming humanized antibodies |
| 08/30/2006 | EP1695983A2 Glucagon-like peptide-1 analogs |
| 08/30/2006 | EP1695979A2 Gapped 2' modified oligonucleotides |
| 08/30/2006 | EP1695970A1 Peptides useful for competitive modulation of dipeptidyl peptidase IV catalysis |
| 08/30/2006 | EP1695722A1 Collagen hemostatic foam |
| 08/30/2006 | EP1695719A1 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery |
| 08/30/2006 | EP1695718A2 Biodegradable polyester and Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| 08/30/2006 | EP1695714A1 Genetically engineered herpes virus for the treatment of tumours |
| 08/30/2006 | EP1695712A2 Oral formulations for the selective inhibition of thrombin comprising boronic acid species |
| 08/30/2006 | EP1695711A2 Parenteral formulations comprising boronic acid species for selective thrombin inhibition |
| 08/30/2006 | EP1695703A2 Anticonvulsant amino acids for the treatment of pain |
| 08/30/2006 | EP1695698A1 Anti-angiogene compositions and methods of use |
| 08/30/2006 | EP1695697A1 Anti-angiogenic compositions and methods of use |
| 08/30/2006 | EP1695061A2 Method for treating neurological disorders |
| 08/30/2006 | EP1694848A1 Novel chimeric plasminogen activators and their pharmaceutical use |
| 08/30/2006 | EP1694841A2 Cancer treatment |
| 08/30/2006 | EP1694840A2 Combination therapy associating a tgf-beta antagonist with a chemotherapeutic agent |
| 08/30/2006 | EP1694839A2 Laminin-5 modulators and uses thereof |
| 08/30/2006 | EP1694709A1 Recombinant anti-cd64-immunotoxins |
| 08/30/2006 | EP1694705A2 Interleukin-10 antibodies |
| 08/30/2006 | EP1694704A2 Peptide hormones zalpha48 and zsig97 |
| 08/30/2006 | EP1694702A2 Methods of inducing il-10 production |
| 08/30/2006 | EP1694701A2 Pp2a/bgamma subunits, modulators thereof, and their uses in the treatment of mental disorders |
| 08/30/2006 | EP1694693A2 Methods for synthesis of encoded libraries |
| 08/30/2006 | EP1694370A1 Wound care products containing keratin |
| 08/30/2006 | EP1694360A2 Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection |
| 08/30/2006 | EP1694359A2 Compositions for reducing bacterial carriage and cns invasion and methods of using same |
| 08/30/2006 | EP1694357A1 Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic |
| 08/30/2006 | EP1694356A2 Regulation of food preference using glp-1 agonists |
| 08/30/2006 | EP1694355A1 Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions |
| 08/30/2006 | EP1694354A1 Method for preventing and treating diabetes using neurturin |
| 08/30/2006 | EP1694353A2 Composition and methods for modulating cns activity |
| 08/30/2006 | EP1694352A2 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 08/30/2006 | EP1694351A2 Glycopegylated follicle stimulating hormone |
| 08/30/2006 | EP1694350A1 Use of caspase-8 inhibitors for modulating hematopoiesis |
| 08/30/2006 | EP1694349A2 Integrin alpha ii beta3 specific antibodies and peptides |
| 08/30/2006 | EP1694348A1 Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists |
| 08/30/2006 | EP1694347A2 Glycopegylated erythropoietin |
| 08/30/2006 | EP1694343A1 Compositions and methods for the treatment of skin damage |
| 08/30/2006 | EP1694342A2 Methods of using gelsolin to treat or prevent bacterial sepsis |
| 08/30/2006 | EP1694324A2 Methods for reducing the effects of stress on skin condition |
| 08/30/2006 | EP1694317A1 Copper antagonist compounds |
| 08/30/2006 | EP1694314A1 Treatment and preventions of asthma |
| 08/30/2006 | EP1694301A2 Methods and compositions for the production of monoclonal antibodies |
| 08/30/2006 | EP1694291A2 Endoparasiticidal agents for topical application |
| 08/30/2006 | EP1694278A2 Glp-1 pharmaceutical compositions |
| 08/30/2006 | EP1694274A2 Glycopegylated granulocyte colony stimulating factor |
| 08/30/2006 | EP1694273A2 Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
| 08/30/2006 | EP1694192A2 Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| 08/30/2006 | EP1694140A1 Peptides having an ace inhibiting effect |
| 08/30/2006 | EP1448593A4 Alpha-fetoprotein peptides and uses thereof |
| 08/30/2006 | EP1445262B1 Peptide derivative, pharmaceutically acceptable salt thereof, process for producing the same, and use thereof |
| 08/30/2006 | EP1432790A4 Regulation of cytotrophoblast cell differentiation and cell migration |
| 08/30/2006 | EP1421198A4 Cell-based high-throughput screening methods |
| 08/30/2006 | EP1377298B1 Exemestane for treating hormono-dependent disorders |
| 08/30/2006 | EP1334188B1 Cd19-specific redirected immune cells |
| 08/30/2006 | EP1297011B1 Diagnostic uses of the t-cell protein tzon7, and of the peptides and antibodies derived therefrom |
| 08/30/2006 | EP1266015B1 Ecdysone receptor-based inducible gene expression system |
| 08/30/2006 | EP1248844B1 Analogs of human basic fibroblast growth factor |
| 08/30/2006 | EP1210430B1 Muc-1 derived peptides |
| 08/30/2006 | EP1180524B1 Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides |
| 08/30/2006 | EP1171604B1 Dna sequence and recombinant production of a graminae allergen |
| 08/30/2006 | EP1155034B1 Formation and anion-exchange of inner crystalline echinocandin b ammonium salts |
| 08/30/2006 | EP1151088B1 Improved phytases |
| 08/30/2006 | EP1137663B1 Purification of echinocandin cyclopeptide compounds |
| 08/30/2006 | EP1133558B1 Compositions and methods for increasing bone mineralization |
| 08/30/2006 | EP1098971B1 Myotilin, an actin-organizing protein |
| 08/30/2006 | EP1036174B1 Novel peptide, apoep1.b, compositions and uses thereof |
| 08/30/2006 | EP0980526B1 Inhibitors of nuclear protein/nuclear receptor interaction |
| 08/30/2006 | EP0972036B1 Prion propagation inhibition by dominant-negative prion protein mutants |
| 08/30/2006 | EP0909316B1 Glial cell line-derived neurotrophic factor receptor |
| 08/30/2006 | EP0796104B1 Delivery of nucleic acid molecules to mucosal tissue |
| 08/30/2006 | EP0755450B1 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE |
| 08/30/2006 | EP0755270B1 Microcapsules, method of making and their use |
| 08/30/2006 | EP0728200B1 Haemophilus transferrin receptor genes |
| 08/30/2006 | EP0529033B1 Nucleotide sequences coding for alpha chain variable regions in human lymphocyte receptors and applications thereof |
| 08/30/2006 | CN1826354A Methods for preventing and treating alzheimer's disease (AD) |
| 08/30/2006 | CN1826353A Novel melanocortin receptor templates, peptides, and use thereof |
| 08/30/2006 | CN1826352A Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof |
| 08/30/2006 | CN1826351A Novel method for the synthesis of perinidopril and the pharmaceutically acceptable salts thereof |
| 08/30/2006 | CN1826350A Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
| 08/30/2006 | CN1826349A Wound care compositions |
| 08/30/2006 | CN1826170A Methods for fabrication, uses and compositions of small spherical particles of hgh prepared by controlled phase separation |
| 08/30/2006 | CN1826140A Combination therapy for the treatment of bacterial infections |
| 08/30/2006 | CN1826137A Inducible ligand for alpha1beta1 integrin and uses |
| 08/30/2006 | CN1826136A Compositions comprising factor ó° and factor IXa for treating haemophilia |
| 08/30/2006 | CN1826135A Unitary combinations of FSH and hCG |
| 08/30/2006 | CN1826134A Pharmaceutical combination of G-CSF and PLGF useful for blood stem cell |
| 08/30/2006 | CN1826133A Method for treating cancer patients undergoing chemotherapy |
| 08/30/2006 | CN1826132A Formulation for a protein pharmaceutical without added human serum albumin (HSA) |
| 08/30/2006 | CN1826131A Formation of novel erythropoietin conjugates using transglutaminase |
| 08/30/2006 | CN1826130A Use of a PAK inhibitor for the treatment of a joint disease |
| 08/30/2006 | CN1826129A Methods and compositions relating to isoleucine boroproline compounds |
| 08/30/2006 | CN1826099A Pharmaceutical composition as solid dosage form and method for manufacturing thereof |
| 08/30/2006 | CN1824777A Human g-protein coupled receptor |